Rett Start May Be Totally Disregarded
It’s quite feasible that an announced start of the Anavex 2-73 clinical trial for little girls with Rett syndrome will affect the AVXL share price in no way whatsoever. How many stock investors, retail or institutional, have ever even heard of “Rett syndrome.” Like some here, it will be confused with some “Rhett” guy in a 1930s movie.
Then, there will be biotech investment experts (we have a number here) who will turn around and say that even if Anavex 2-73 gets FDA approval to treat Rett syndrome, with only a few thousand girls with the malady Anavex Life Science Corp could never make enough funds to even try to make and sell it for this “rare” disease. “There are other biotechs, fully established and profitable, that should be bought. Stay away from little Anavex. No future.”
The general investment public, retail and institutional, is unable to comprehend or appreciate the unique, proprietary, game-changing outcomes that will occur when – perhaps in a few years — Anavex Life Science Corp gets to sell any of the drugs in its pipeline.
Very good chance that will be in Australia, or perhaps Spain. AVXL share prices can’t take off until the general public reads stories about people (not the drug itself) that have gained suppression of CNS disease degeneration, or, even, had symptoms reversed.
When millions of families of American Alzheimer’s victims read of profound treatment and prevention outcomes with Anavex 2-73 in some foreign country, news media will write “interesting” stories on the phenomenon; asking what keeps that drug from being sold in the US. FDA: “Too dangerous, not tested enough to know if it’s safe or effective.”
Till all of that starts, two or three years from now, I’m just sitting back, stupidly holding my few hundred AVXLs. Dead money, for now.
But, then....!
